Acarix
Develops AI-powered acoustic devices for non-invasive diagnosis of coronary artery disease.
ACARIX | ST
Overview
Corporate Details
- ISIN(s):
- SE0009268717 (+1 more)
- LEI:
- 549300KP2XS4513DEI67
- Country:
- Sweden
- Address:
- HYLLIE BOULEVARD 34 5 TR, 215 32 MALMÖ
- Website:
- https://www.acarix.com/
- Sector:
- Manufacturing
Description
Acarix is a medical device company focused on developing solutions for the rapid, non-invasive diagnosis of Coronary Artery Disease (CAD) at the point of care. Its primary product, the CADScor® System, is a diagnostic aid that uses AI-powered acoustic technology. The system analyzes coronary blood flow with a highly sensitive sensor and advanced computational processing to calculate a patient-specific CAD-score. This score, combined with risk factors, allows healthcare professionals to immediately stratify the risk of significant coronary stenosis in symptomatic patients. The radiation-free device is designed as a frontline tool to help rule out CAD, providing actionable results to improve diagnostic pathways. The CADScor® System has received both CE marking and FDA De Novo clearance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Acarix filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Acarix
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Acarix via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Aamir Mahmood | Other | Buy | 1,382,000 | 317,860.00 SEK |
| 2025-02-13 | Aamir Mahmood | Other | Buy | 918,257 | 192,833.97 SEK |
Peer Companies
